Clinical Trials on Mediastinal Lymphadenopathy in Russian Federation

Total 5 results

National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
Tomsk National Research Medical Center of the Russian...

Completed

Combined Air-plasma Flow and Nitric Oxide Therapy in Cardiac Surgery

Mediastinitis

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Burkitt Lymphoma | Diffuse Large B-cell Lymphoma | Primary CNS Lymphoma | Primary Mediastinal Lymphoma | Non-hodgkin Lymphoma,B Cell

Russian Federation
Pharming Technologies B.V.

Active, not recruiting

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Activated PI3Kdelta Syndrome (APDS); PASLI Disease

United States, Belarus, Czechia, Germany, Italy, Netherlands, Russian Federation
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine

3

Subscribe